| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GPC3 |
| Uniprot No | P51654 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-559aa |
| 氨基酸序列 | QPPPPPPDATCHQVRSFFQRLQPGLKWVPETPVPGSDLQVCLPKGPTCCSRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEIVVRHAKNYTNAMFKNNYPSLTPQAFEFVGEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYTQLMNPGLPDSALDINECLRGARRDLKVFGNFPKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMWYCSYCQGLMMVKPCGGYCNVVMQGCMAGVVEIDKYWREYILSLEELVNGMYRIYDMENVLLGLFSTIHDSIQYVQKNAGKLTTTIGKLCAHSQQRQYRSAYYPEDLFIDKKVLKVAHVEHEETLSSRRRELIQKLKSFISFYSALPGYICSHSPVAENDTLCWNGQELVERYSQKAARNGMKNQFNLHELKMKGPEPVVSQIIDKLKHINQLLRTMSMPKGRVLDKNLDEEGFESGDCGDDEDECIGGSGDGMIKVKNQLRFLAELAYDLDVDDAPGNSQQATPKDNEISTFHNLGNVH |
| 预测分子量 | 62.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GPC3重组蛋白的3-4篇参考文献的简要概述(注：文献为示例性内容，实际引用需核实原文)：
---
1. **文献名称**：*"A recombinant GPC3 protein vaccine induces protective immunity against hepatocellular carcinoma in mice"*
**作者**：Zhang Y, et al. (2015)
**摘要**：研究报道了利用重组GPC3蛋白作为疫苗的免疫治疗效果，通过在小鼠肝癌模型中诱导特异性T细胞应答和抗体产生，显著抑制肿瘤生长，提示其在肝癌免疫治疗中的潜力。
---
2. **文献名称**：*"Expression and purification of recombinant human GPC3 in Escherichia coli for antibody production"*
**作者**：Li H, et al. (2018)
**摘要**：该研究优化了人源GPC3蛋白在大肠杆菌中的可溶性表达条件，并通过镍柱亲和层析技术高效纯化，获得高纯度重组蛋白，为后续抗体开发及功能研究提供基础。
---
3. **文献名称**：*"Development of a monoclonal antibody against recombinant GPC3 for early diagnosis of hepatocellular carcinoma"*
**作者**：Wang X, et al. (2020)
**摘要**：利用重组GPC3蛋白制备单克隆抗体，验证其在肝癌患者血清中的高灵敏度和特异性检测能力，表明其作为非侵入性诊断标志物的临床应用价值。
---
4. **文献名称**：*"Structural characterization of recombinant GPC3 and its interaction with Wnt3a"*
**作者**：Suzuki T, et al. (2012)
**摘要**：通过重组表达获得GPC3胞外结构域，结合X射线晶体学解析其三维结构，并揭示其与Wnt3a蛋白的结合机制，为靶向GPC3的癌症治疗策略提供结构生物学依据。
---
**注意**：以上文献信息为模拟示例，实际研究中需根据具体论文内容调整作者、年份及摘要细节。建议通过PubMed、Web of Science等数据库检索最新文献获取准确信息。
Glypican-3 (GPC3), a member of the glypican family, is a heparan sulfate proteoglycan anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linker. It plays critical roles in embryonic development by modulating signaling pathways such as Wnt, Hedgehog, and YAP/TAZ, influencing cell proliferation, differentiation, and tissue morphogenesis. In adults, GPC3 expression is largely restricted, but it becomes aberrantly overexpressed in several cancers, particularly hepatocellular carcinoma (HCC), where it serves as a tumor-specific biomarker and potential therapeutic target. Its oncogenic role involves promoting cell growth, inhibiting apoptosis, and enhancing tumor angiogenesis.
Recombinant GPC3 protein, produced through genetic engineering in systems like mammalian cells, bacteria, or yeast, retains the functional domains of native GPC3 for research and clinical applications. This includes the N-terminal globular domain for ligand interactions and the C-terminal GPI anchor region. Recombinant GPC3 is widely used to study tumor biology, screen therapeutic antibodies, and develop diagnostic assays. In immunotherapy, it serves as a target for chimeric antigen receptor (CAR) T-cell therapies, monoclonal antibodies (e.g., codrituzumab), and cancer vaccines. Its tumor-specific expression minimizes off-target effects, making it a promising candidate for precision oncology. However, challenges remain in optimizing delivery systems and overcoming tumor heterogeneity. Ongoing research focuses on combining GPC3-targeted therapies with checkpoint inhibitors or conventional treatments to enhance efficacy.
×
